Boothbay Fund Management LLC grew its position in shares of PAREXEL International Co. (NASDAQ:PRXL) by 551.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,085 shares of the medical research company’s stock after buying an additional 17,000 shares during the quarter. Boothbay Fund Management LLC’s holdings in PAREXEL International were worth $1,769,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in PAREXEL International by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 4,205,566 shares of the medical research company’s stock worth $365,506,000 after buying an additional 39,302 shares during the last quarter. State Street Corp raised its position in PAREXEL International by 4.3% during the 2nd quarter. State Street Corp now owns 1,744,373 shares of the medical research company’s stock worth $151,607,000 after buying an additional 71,255 shares during the last quarter. Alpine Associates Management Inc. purchased a new position in PAREXEL International during the 2nd quarter worth $113,716,000. CNH Partners LLC purchased a new position in PAREXEL International during the 2nd quarter worth $109,948,000. Finally, JPMorgan Chase & Co. raised its position in PAREXEL International by 1,008.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 982,186 shares of the medical research company’s stock worth $85,362,000 after buying an additional 893,551 shares during the last quarter. Institutional investors own 87.45% of the company’s stock.
PAREXEL International Co. (PRXL) opened at $88.08 on Friday. The company has a current ratio of 1.45, a quick ratio of 1.45 and a debt-to-equity ratio of 1.01. PAREXEL International Co. has a twelve month low of $51.16 and a twelve month high of $88.10.
Separately, Zacks Investment Research upgraded shares of PAREXEL International from a “hold” rating to a “buy” rating and set a $98.00 price objective for the company in a research report on Thursday, August 31st. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $80.76.
COPYRIGHT VIOLATION WARNING: This news story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://ledgergazette.com/2017/12/08/boothbay-fund-management-llc-has-1-77-million-holdings-in-parexel-international-co-prxl.html.
PAREXEL International Profile
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Co. (NASDAQ:PRXL).
Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with MarketBeat.com's FREE daily email newsletter.